

Mã³nica Patricia Ballesteros Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/116989/publications.pdf>

Version: 2024-02-01

31
papers

626
citations

623734

14
h-index

610901

24
g-index

34
all docs

34
docs citations

34
times ranked

1249
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | COVID-19 coagulopathy: An in-depth analysis of the coagulation system. <i>European Journal of Haematology</i> , 2020, 105, 741-750. | 2.2 | 93 |
| 2 | Interobserver variance in myelodysplastic syndromes with less than 5% bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2% blasts. <i>Annals of Hematology</i> , 2015, 94, 565-573. | 1.8 | 62 |
| 3 | False-positive <i>Aspergillus</i> Antigenemia Due to Blood Product Conditioning Fluids. <i>Clinical Infectious Diseases</i> , 2012, 55, e22-e27. | 5.8 | 52 |
| 4 | An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression. <i>Blood</i> , 2009, 114, 5081-5090. | 1.4 | 45 |
| 5 | Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. <i>Journal of Medical Screening</i> , 2021, 28, 389-404. | 2.3 | 44 |
| 6 | Validation of the FACT-G scale for evaluating quality of life in cancer patients in Colombia. <i>Quality of Life Research</i> , 2011, 20, 19-29. | 3.1 | 41 |
| 7 | Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. <i>Salud Publica De Mexico</i> , 2008, 50, 276-285. | 0.4 | 39 |
| 8 | Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells. <i>Leukemia Research</i> , 2009, 33, 395-406. | 0.8 | 26 |
| 9 | Methodological systematic review identifies major limitations in prioritization processes for updating. <i>Journal of Clinical Epidemiology</i> , 2017, 86, 11-24. | 5.0 | 25 |
| 10 | Evidence mapping and quality assessment of systematic reviews on therapeutic interventions for oral cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 117-130. | 1.9 | 24 |
| 11 | Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. <i>Cancers</i> , 2019, 11, 1364. | 3.7 | 23 |
| 12 | Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST). <i>BMC Medical Research Methodology</i> , 2017, 17, 135. | 3.1 | 18 |
| 13 | Extending the RIGHT statement for reporting adapted practice guidelines in healthcare: the RIGHT-Ad@pt Checklist protocol. <i>BMJ Open</i> , 2019, 9, e031767. | 1.9 | 17 |
| 14 | A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. <i>Annals of Internal Medicine</i> , 2022, 175, 710-719. | 3.9 | 16 |
| 15 | The UpPriority tool was developed to guide the prioritization of clinical guideline questions for updating. <i>Journal of Clinical Epidemiology</i> , 2020, 126, 80-92. | 5.0 | 15 |
| 16 | Barriers to Advance Care Planning Implementation in Health care: An Umbrella Review with Implications for Evidence-Based Practice. <i>Worldviews on Evidence-Based Nursing</i> , 2021, 18, 254-263. | 2.9 | 14 |
| 17 | Development of a prioritisation tool for the updating of clinical guideline questions: the UpPriority Tool protocol. <i>BMJ Open</i> , 2017, 7, e017226. | 1.9 | 11 |
| 18 | Current practices and challenges in adaptation of clinical guidelines: a qualitative study based on semistructured interviews. <i>BMJ Open</i> , 2021, 11, e053587. | 1.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. BMC Hematology, 2016, 16, 14. | 2.6 | 7 |
| 20 | Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation. Seminars in Hematology, 2018, 55, 189-196. | 3.4 | 6 |
| 21 | Colorectal cancer guidelines seldom include the patient perspective. Journal of Clinical Epidemiology, 2019, 116, 84-97. | 5.0 | 6 |
| 22 | Healthcare professionals'™ opinions, barriers and facilitators towards low-value clinical practices in the hospital setting. Gaceta Sanitaria, 2020, 34, 459-467. | 1.5 | 5 |
| 23 | Description of the Protocols for Randomized Controlled Trials on Cancer Drugs Conducted in Spain (1999-2003). PLoS ONE, 2013, 8, e79684. | 2.5 | 5 |
| 24 | Cancer randomized trials showed that dissemination bias is still a problem to be solved. Journal of Clinical Epidemiology, 2016, 77, 84-90. | 5.0 | 4 |
| 25 | Evidence mapping based on systematic reviews of therapeutic interventions for soft tissue sarcomas. Clinical and Translational Oncology, 2019, 21, 1398-1412. | 2.4 | 3 |
| 26 | Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations. Cancers, 2021, 13, 3001. | 3.7 | 2 |
| 27 | Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) - Is the Threshold of 20% Bone Marrow Blasts Reproducible?. Blood, 2021, 138, 2607-2607. | 1.4 | 2 |
| 28 | Delayed Hypersensitivity Reaction to Lenalidomide: 2 Different Clinical Patterns in the Same Patient. Journal of Investigational Allergology and Clinical Immunology, 2019, 29, 309-311. | 1.3 | 1 |
| 29 | Teaching and learning how to make informed health choices: A Protocol for a context analysis in Spanish primary schools. F1000Research, 2021, 10, 312. | 1.6 | 1 |
| 30 | Teaching and learning how to make informed health choices: A Protocol for a context analysis in Spanish primary schools. F1000Research, 2021, 10, 312. | 1.6 | 0 |
| 31 | Inter-Observer Discordance With The Diagnosis Of Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts: Unilineage Vs Multilineage Dysplasia and Reproducibility Of The Threshold Of 2% Blasts. Blood, 2013, 122, 2768-2768. | 1.4 | 0 |